ArticleAmerican journal of respiratory and critical care medicine2020
Synergistic Signaling of TLR and IFNα/β Facilitates Escape of IL-18 Expression from Endotoxin Tolerance.
Open access · greenAbstract read
In one paragraph
Article in American journal of respiratory and critical care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 60 citations in OpenAlex.
- Distinct Gene Expression Signatures Characterize Strong Clinical Responders Versus Nonresponders to Canakinumab in Children With Systemic Juvenile Idiopathic Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2021Trial
- A Multifaceted Interplay Among Hemophagocytosis, Interleukin-18, and Type I Interferon Distinguishes Still Disease From Other Autoinflammatory Diseases.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Is clonal haematopoiesis the missing link between lupus and cardiovascular disease?Rheumatology (Oxford, England) · 2026Review
- Type I Interferon Signature is Associated With Lung Disease, Drug-Associated Immune Reactions, and Genetic Variation in Interferon-Linked Pathways in Still Disease.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Type I Interferon-Driven Monocyte Dysregulation and MAS-associated CD8bioRxiv : the preprint server for biology · 2026Article
- STAT1 drives the immune landscape of murine Toll-like receptor 9-induced liver inflammation.JHEP reports : innovation in hepatology · 2026Article
- Langerhans Cell Modulation in Atopic Dermatitis Is TLR2/SOCS1-Dependent and JAK Inhibitor-Sensitive.Allergy · 2025Article
- Subtype-associated complexity and prognostic significance of the NLRP3 inflammasome landscape in pancreatic neoplasms.The journal of pathology. Clinical research · 2025Article
- Weal and woe of interleukin-18 in the T cell therapy of cancer.Journal for immunotherapy of cancer · 2025Review
- TPL2 kinase activity is required forFrontiers in immunology · 2025Article
- Investigating pulmonary inflammation and injury after progressive systemic inflammation in preterm fetal sheep.Frontiers in physiology · 2025Article
- Type I interferon regulates interleukin-1beta and IL-18 production and secretion in human macrophages.Life science alliance · 2024Article
- Tofacitinib for the treatment of severe rare skin diseases: a narrative review.European journal of clinical pharmacology · 2024Review
- Cytokine Storm Syndrome Associated with Systemic Juvenile Idiopathic Arthritis.Advances in experimental medicine and biology · 2024Review
- JAK Inhibitors in Cytokine Storm Syndromes.Advances in experimental medicine and biology · 2024Review
- Murine Models of Secondary Cytokine Storm Syndromes.Advances in experimental medicine and biology · 2024Review
- Biological and clinical roles of IL-18 in inflammatory diseases.Nature reviews. Rheumatology · 2024Review
- Treatment of systemic juvenile idiopathic arthritis.Nature reviews. Rheumatology · 2023Review
- Type 1 Interferon-Stimulated Gene Expression and Disease Activity in Pediatric Rheumatic Diseases: No Composite Scores Needed?ACR open rheumatology · 2023Article
- Type I interferon signature and cycling lymphocytes in macrophage activation syndrome.The Journal of clinical investigation · 2023Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 5 institutions in 3 countries.
Emely VerweyenDepartment of Pediatric Rheumatology and Immunology, University Children's Hospital, Münster, Germany.
Dirk HolzingerDepartment of Pediatric Hematology-Oncology, University of Duisburg-Essen, Essen, Germany.
Toni WeinhageDepartment of Pediatric Rheumatology and Immunology, University Children's Hospital, Münster, Germany.
Claas HinzeDepartment of Pediatric Rheumatology and Immunology, University Children's Hospital, Münster, Germany.ORCID 0000-0001-9247-4729
Helmut WittkowskiDepartment of Pediatric Rheumatology and Immunology, University Children's Hospital, Münster, Germany.
Peter PickkersDepartment of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID 0000-0002-1104-4303
Sabrin AlbeituniDivision of Cancer Predisposition, St. Jude Children's Research Hospital, Memphis, Tennessee; and.
Katherine VerbistDivision of Cancer Predisposition, St. Jude Children's Research Hospital, Memphis, Tennessee; and.
Kim E NicholsDivision of Cancer Predisposition, St. Jude Children's Research Hospital, Memphis, Tennessee; and.ORCID 0000-0002-5581-6555
Grant SchulertDepartment of Rheumatology, Cincinnati Children's Hospital Medical Center and.ORCID 0000-0001-5923-7051
Alexei GromDepartment of Rheumatology, Cincinnati Children's Hospital Medical Center and.
Dirk FoellDepartment of Pediatric Rheumatology and Immunology, University Children's Hospital, Münster, Germany.
Christoph KesselDepartment of Pediatric Rheumatology and Immunology, University Children's Hospital, Münster, Germany.ORCID 0000-0002-0638-2949
University Hospital Münster · DESt. Jude Children's Research Hospital · USCincinnati Children's Hospital Medical Center · USRadboud University Nijmegen · NLUniversity of Duisburg-Essen · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAnimalsAntibodies, Monoclonal, HumanizedDisease Models, AnimalEndotoxinsGene ExpressionHumansImmune ToleranceInterferon-alphaInterferon-betaInterleukin-18Interleukin-1betaInterleukin 1 Receptor Antagonist ProteinIn Vitro TechniquesJanus Kinase InhibitorsLipopolysaccharidesAntibodies, Monoclonal, HumanizedcanakinumabEndotoxinsInterferon-alphaInterferon-betaInterleukin-18Interleukin-1betaInterleukin 1 Receptor Antagonist ProteinJanus Kinase InhibitorsLipopolysaccharidesPiperidinesPyrimidinesPyrrolestocilizumabtofacitinibToll-Like ReceptorsTumor Necrosis Factor Inhibitorsendotoxin toleranceexperimental human endotoxemiaIL-18macrophage activation syndrometype I IFN
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.